Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Companyâ€™s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâ€™s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Employees

1,000

Sector

Advanced Medical Equipment & Technology

More about the company

Delayed OTC Markets 19:56:45 26/03/2026 GMT			5-day change	1st Jan Change
0.0550 ^USD	+5.77%		-.--%	-56.35%

03-26	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-26	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI

Market Cap	3.83M 3.3M 3.12M 2.83M 5.31M 366M 5.34M 37.1M 14.27M 186M 14.38M 14.06M 588M	P/E 2023	40.3x	P/E 2024	89x
Enterprise Value	38.02M 32.76M 31.02M 28.12M 52.75M 3.63B 53.01M 368M 142M 1.85B 143M 140M 5.84B	EV / Sales 2023	2.17x	EV / Sales 2024	1.5x
Free-Float	38.37%	Yield 2023 *	-	Yield 2024	-

03-26	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-26	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI
03-26	Zynex, Inc. Emerged from Bankruptcy	CI
03-20	Court confirms Zynex plan of reorganization on March 19, 2026 - SEC filing	RE
03-19	Third Amended Reorganization Plan Approved for Zynex, Inc.	CI
02-19	Zynex Inc says SEC concluded investigation into Zynex, no enforcement action planned	RE
02-17	Zynex Inc resolves federal investigation into business practices	RE
02-10	Notice of Auction Cancellation and Designation of Successful Bidder Filed by Zynex, Inc.	CI
02-07	Third Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
02-04	Zynex, Inc. Announces New In-Network Provider Status with Humana	CI
02-02	Second Amended Joint Disclosure Statement Conditionally Approved and Combined Hearing of Second Amended Disclosure Statement and Reorganization Plan Approved for Zynex, Inc.	CI
02-01	Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
01-29	First Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI

01/08/25	RBC Capital Adjusts Price Target on Zynex to $2 From $3, Maintains Sector Perform Rating	MT
01/08/25	HC Wainwright Downgrades Zynex to Neutral From Buy	MT
31/07/25	Medtech Zynex's Q2 revenue falls more than expected, names new CEO, suspends forecast	RE
15/07/25	RBC Cuts Price Target on Zynex to $3 From $4, Keeps Sector Perform Rating	MT
30/04/25	RBC Cuts Price Target on Zynex to $4 From $5, Keeps Sector Perform Rating	MT

Zynex, Inc. Share Price

Stocks

ZYXI

US98986M1036

Advanced Medical Equipment & Technology

Valuation : Zynex, Inc.

Chart: Zynex, Inc.

Latest news : Zynex, Inc.

Last Transcript : Zynex, Inc.

Analysts' recommendations : Zynex, Inc.

Press Releases : Zynex, Inc.

News in other languages : Zynex, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Zynex, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

03-27	ZYXIQ Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-26	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR
03-26	ZYXIQ SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit - ZYXIQ	PR
03-24	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR

27/12/22	Top 50 Small-caps 2023
21/12/22	Top 50 Small-caps 2023
21/10/21	Los valores del Nasdaq con mayor crecimiento
21/10/21	Les actions du Nasdaq avec la plus forte croissance

Current year	0.02	0.13
1 year	0.02	2.1
3 years	0.02	13.77
5 years	0.02	17.25
10 years	0.02	27.02

Manager	Title	Age	Since
Steven Dyson CEO	Chief Executive Officer	53	17/08/2025
Vikram Bajaj DFI	Director of Finance/CFO	50	17/08/2025
John Bibb LAW	General Counsel	53	17/08/2025

Director	Title	Age	Since
Vikram Bajaj BRD	Director/Board Member	50	25/03/2026
John Bibb BRD	Director/Board Member	53	25/03/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/03/26	Barry Michaels	Issuer sale	Director	80,001	0.2633%
26/03/26	Michael Cress	Issuer sale	Director	95,000	0.3126%
26/03/26	Joshua Disbrow	Issuer sale	Director	102,000	0.3357%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ZYNEX, INC.	+5.77%	-.--%	-96.28%	-99.32%	1.69M
THERMO FISHER SCIENTIFIC, INC.	+1.10%	-0.65%	+27.19%	+19.34%	225B
DANAHER CORPORATION	-0.19%	-3.62%	+5.31%	-19.41%	141B
INTUITIVE SURGICAL, INC.	+2.41%	+0.67%	-17.91%	+22.42%	130B
BOSTON SCIENTIFIC CORPORATION	-0.28%	-10.08%	-58.15%	-19.54%	62.29B
SIEMENS HEALTHINEERS AG	-0.49%	-1.97%	-19.72%	-15.81%	49.39B
EDWARDS LIFESCIENCES CORPORATION	-2.77%	-6.15%	+8.77%	+14.99%	48.63B
AGILENT TECHNOLOGIES, INC.	+2.66%	-2.61%	+19.22%	+30.28%	41.42B
WATERS CORPORATION	+1.67%	-0.25%	+38.24%	+56.84%	40.12B
RESMED, INC.	-0.60%	-4.41%	-19.20%	+46.52%	31.23B
Average	+0.93%	-5.38%	-11.25%	+3.63%	76.97B
Weighted average by Cap.	+0.67%	-2.50%	+2.73%	+10.75%

	2023	2024
Net sales	184M 159M 150M 136M 256M 17.61B 257M 1.79B 687M 8.96B 692M 677M 28.31B	192M 166M 157M 142M 267M 18.38B 268M 1.86B 717M 9.35B 722M 707M 29.54B
Net income	9.73M 8.39M 7.94M 7.2M 13.5M 930M 13.57M 94.3M 36.26M 473M 36.55M 35.75M 1.49B	2.99M 2.58M 2.44M 2.21M 4.15M 286M 4.17M 29.01M 11.16M 146M 11.24M 11M 460M
Net Debt	31.59M 27.22M 25.77M 23.36M 43.82M 3.02B 44.04M 306M 118M 1.54B 119M 116M 4.85B	34.19M 29.46M 27.9M 25.28M 47.43M 3.27B 47.68M 331M 127M 1.66B 128M 126M 5.25B